RxDoctor Payments Data

Aamir Iqbal, MD

Hospitalist · Thousand Oaks, CANPI 1174054019

Payments from drug & device makers

$3,422in general payments, 2019–2025

Across 175 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$901
  • Novartis$303
  • Johnson & Johnson$245
  • AbbVie$232
  • Novo Nordisk$232
  • AstraZeneca$225
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,38999%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,422 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$420,934
Medicare patients
437
Services billed
5,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$33,174
EliquisApixaban21$22,052
OzempicSemaglutide13$19,507
FarxigaDapagliflozin Propanediol13$14,750
Repatha SureclickEvolocumab15$13,839
Levothyroxine Sodium95$1,345
Losartan Potassium105$1,237
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,203
Atorvastatin Calcium117$1,143
Pantoprazole Sodium60$1,136
Tamsulosin Hcl56$1,120
Rosuvastatin Calcium90$949
SynthroidLevothyroxine Sodium12$844
Ipratropium Bromide13$737
Omeprazole28$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$170$33,17427 claims
PfizerEliquis$42$22,05221 claims
Novo NordiskOzempic$232$19,50713 claims
AstraZenecaFarxiga$225$14,75013 claims
AbbVieSynthroid$232$84412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Thousand Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →